Results 61 to 70 of about 7,028 (198)
HPV‐6 Positive Eruptive Verruca Vulgaris After Upadacitinib Initiation for Severe Atopic Dermatitis
JEADV Clinical Practice, EarlyView.ABSTRACT Oral JAK‐1 inhibitors for atopic dermatitis (AD) are associated with an increased risk of cutaneous viral infections, particularly herpes zoster. Emerging case reports further suggest a link to eruptive human papillomavirus (HPV) disease. A 23‐year‐old transgender man (female‐to‐male) with severe AD developed a rapidly disseminating eruption ...
Mohammed Shanshal +2 more
wiley +1 more source
Rheumatology &Autoimmunity, EarlyView.Sera from patients with anti‐MDA5‐positive dermatomyositis‐associated interstitial lung disease (ILD) exhibit significantly higher type I interferon (IFN‐I) bioactivity and interferon‐stimulated gene‐inducing activity compared to anti‐ARS‐positive ILD and healthy controls.
Shohei Nakamura +3 more
wiley +1 more source
Data_Sheet_1_Treatment of atopic dermatitis with upadacitinib: adcare single center experience.pdf [PDF]
IntroductionThe role of upadacitinib in the management of moderate to severe atopic dermatitis seems promising, but more data on its efficacy and safety are needed.
Daria S. Fomina (9213848) +11 more
core +1 more source
Benzalkonium Chloride in Eye Drops Causing Allergic Contact Dermatitis: A Case Series
Australasian Journal of Dermatology, EarlyView.ABSTRACT We present three patients who developed allergic contact dermatitis (ACD) from benzalkonium chloride (BAK) in ophthalmic drops. BAK is a preservative commonly found in ophthalmic formulations and there is a rising trend of ACD to this allergen. The irritant and sensitising properties of BAK on the ocular mucosa will be discussed.
Arav Kannen +2 more
wiley +1 more source
ACR Open RheumatologyObjective Upadacitinib improved the signs and symptoms of non‐radiographic axial spondyloarthritis (nr‐axSpA) versus placebo over 14 weeks in the primary analysis of the SELECT‐AXIS 2 nr‐axSpA study.
Filip Van den Bosch +11 more
doaj +1 more source
Allergy, EarlyView.ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter +20 more
wiley +1 more source
Treatment with Upadacitinib in Difficult-to-Treat (D2T) Psoriatic Arthritis (PsA): A National Multicenter Study of the First 134 Patients in Clinical Practice [PDF]
Upadacitinib has demonstrated efficacy in psoriatic arthritis in clinical trials, but its real-world performance in difficult-to-treat PsA remains underexplored.
Rosario Garcia-Vicuña +21 more
core +1 more source
Clinical and Translational Science, 2022 Upadacitinib is an oral Janus kinase inhibitor approved for the treatment of rheumatoid arthritis (RA) and recently approved by the European Medicines Agency for the treatment of psoriatic arthritis (PsA).
Elena Muensterman +4 more
doaj +1 more source
Review Article: The Impact of the Gut Microbiome on Ulcerative Colitis Pharmacotherapy
Alimentary Pharmacology &Therapeutics, EarlyView.The gut microbiome modulates ulcerative colitis pharmacotherapy through microbial drug metabolism, immune regulation and altered drug bioavailability. Microbial composition influences response to aminosalicylates, corticosteroids, immunomodulators, biologics and small molecules, while microbiome‐targeted therapies show emerging promise.
Kate Collins +6 more
wiley +1 more source
Dermatology and TherapyIntroduction Atopic dermatitis (AD) is characterized by intense itch and other symptoms that negatively impact quality of life (QoL). This study evaluates the effect of upadacitinib (an oral selective Janus kinase inhibitor) monotherapy on patient ...
Eric L. Simpson +17 more
doaj +1 more source